Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allocetra-OTS in Knee Osteoarthritis
2023-508748-23-00Phase 2Completed
- Sponsor
- Enlivex Therapeutics
- Start
- Mar 2024
- Modality
- Cell Therapies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in knee osteoarthritis (OA) comparing Allocetra-OTS with Placebo (2 arms). Primary endpoint: Number and severity of adverse events and serious adverse events. Started Mar 2024; status: completed.
02
Drugs
Allocetra
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2023-508748-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508748-23-00.